TransMedics Group (NASDAQ:TMDX) Upgraded at Needham & Company LLC

Needham & Company LLC upgraded shares of TransMedics Group (NASDAQ:TMDX) from a hold rating to a buy rating in a report released on Thursday morning, MarketBeat.com reports. Needham & Company LLC currently has $148.00 target price on the stock.

TMDX has been the topic of several other research reports. Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a research note on Wednesday, October 8th. Stifel Nicolaus initiated coverage on TransMedics Group in a research note on Thursday, September 4th. They set a “hold” rating and a $115.00 target price on the stock. Canaccord Genuity Group reissued a “buy” rating and set a $142.00 target price on shares of TransMedics Group in a research note on Tuesday, October 14th. Evercore ISI started coverage on TransMedics Group in a research note on Tuesday, September 16th. They issued an “outperform” rating and a $155.00 price objective on the stock. Finally, Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Eight research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, TransMedics Group presently has an average rating of “Moderate Buy” and a consensus price target of $130.73.

TransMedics Group Stock Up 1.2%

Shares of TMDX opened at $130.52 on Thursday. The business’s 50 day moving average is $115.94 and its 200 day moving average is $115.56. The company has a market capitalization of $4.45 billion, a PE ratio of 67.63 and a beta of 2.08. TransMedics Group has a 12-month low of $55.00 and a 12-month high of $145.50. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.44. The company had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The firm’s quarterly revenue was up 37.7% on a year-over-year basis. During the same quarter last year, the company earned $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. Research analysts expect that TransMedics Group will post 1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TransMedics Group

Institutional investors and hedge funds have recently modified their holdings of the stock. OneDigital Investment Advisors LLC boosted its holdings in shares of TransMedics Group by 52.6% in the 1st quarter. OneDigital Investment Advisors LLC now owns 5,989 shares of the company’s stock worth $403,000 after purchasing an additional 2,065 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of TransMedics Group by 2.8% in the 1st quarter. Principal Financial Group Inc. now owns 198,427 shares of the company’s stock worth $13,350,000 after purchasing an additional 5,480 shares during the period. Vontobel Holding Ltd. purchased a new position in shares of TransMedics Group in the 1st quarter worth approximately $291,000. New York State Teachers Retirement System boosted its holdings in TransMedics Group by 183.2% during the 1st quarter. New York State Teachers Retirement System now owns 21,949 shares of the company’s stock valued at $1,477,000 after acquiring an additional 14,200 shares during the period. Finally, Peregrine Capital Management LLC boosted its holdings in TransMedics Group by 3.4% during the 1st quarter. Peregrine Capital Management LLC now owns 68,390 shares of the company’s stock valued at $4,601,000 after acquiring an additional 2,250 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.